Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an <i>in vivo</i> tool compound for neuroinflammatory disorders
David Harrison(University of Notre Dame), Alan P. Watt(Chelmsford and Essex Hospital), Jane Scanlon(Chelmsford and Essex Hospital), Nicola Lindsay, Zsofia Digby, Christopher A. Gabel(University of North Carolina at Chapel Hill), Andy Billinton(Chelmsford and Essex Hospital), Mark G. Bock, Peter Thornton(Community Health Systems - Lutheran Hospital), Pamela J. Smolak(University of North Carolina at Chapel Hill), Nicholas Clarke, Heather Wescott(University of North Carolina at Chapel Hill), Valérie Reader(Chelmsford and Essex Hospital)
Cited by 3
Related Papers
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders
|Journal of Medicinal Chemistry|2023|62
Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing
|European Journal of Pharmacology|2014|54
Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796
|Journal of Pharmacology and Experimental Therapeutics|2024|51
Myocardial Hypertrophy Resulting from Low Dosage Isoproterenol Administration in Rats
|Experimental Biology and Medicine|1971|49
Engineering transglycosidase activity into a GH51 α-l-arabinofuranosidase
|New Biotechnology|2013|35